Two Milestone Studies in Liver Cancer Immunotherapy

Immunotherapy has changed the playing field for multiple cancers, and prime time for unresectable liver cancers may be here now. This issue of NEJM Evidence includes two trials describing novel immunotherapy options for patients with biliary tract cancer and hepatocellular carcinoma. Oh et al.1 describe the results of the TOPAZ-1 trial, which resulted in improved overall survival for patients with biliary tract cancer in the frontline setting — the first real advance in more than a decade.2 Abou-Alfa et al.3 present results from the HIMALAYA study.